Alx Oncology Holdings (ALXO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alx Oncology Holdings (ALXO) has a cash flow conversion efficiency ratio of -0.118x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.06 Million) by net assets ($136.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Alx Oncology Holdings for the company's overall valuation and market capitalisation.
Alx Oncology Holdings - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alx Oncology Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alx Oncology Holdings ranked by their cash flow conversion efficiency. See Alx Oncology Holdings cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hansae Co
KO:105630
|
0.006x |
|
Ernst Russ AG
XETRA:HXCK
|
0.066x |
|
Gedik Yatirim Menkul Degerler AS
IS:GEDIK
|
-0.435x |
|
Toubani Resources Ltd
AU:TRE
|
-0.052x |
|
Otovo AS
OL:OTOVO
|
-0.387x |
|
Nova Minerals Ltd
AU:NVA
|
-0.028x |
|
Groupe Pizzorno Environnement SA
PA:GPE
|
0.332x |
|
Jain Irrigation Systems Limited
NSE:JISLJALEQS
|
0.032x |
Annual Cash Flow Conversion Efficiency for Alx Oncology Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Alx Oncology Holdings from 2018 to 2025. View ALXO share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $25.98 Million | $-84.14 Million | -3.239x | -201.83% |
| 2024-12-31 | $113.62 Million | $-121.91 Million | -1.073x | -56.15% |
| 2023-12-31 | $189.71 Million | $-130.36 Million | -0.687x | -102.91% |
| 2022-12-31 | $263.46 Million | $-89.22 Million | -0.339x | -80.54% |
| 2021-12-31 | $363.05 Million | $-68.10 Million | -0.188x | -110.58% |
| 2020-12-31 | $429.85 Million | $-38.29 Million | -0.089x | -100.17% |
| 2019-12-31 | $-276.00K | $-14.25 Million | 51.627x | +3683.35% |
| 2018-12-31 | $9.15 Million | $-13.19 Million | -1.441x | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more